Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Zhiwei Meng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China. Hauptthemen laut MEDLINE: Thrombosis, Factor XIIa. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Provincial Key Research and Development Plan, Intelligent Manufacturing Institute, Hefei University of Technology.
Abstract (Originalsprache)
Thrombo-inflammation is closely associated with a few severe cardiovascular and infectious diseases. Factor XIIa (FXIIa) in the intrinsic coagulation pathway plays a pivotal role in the development of thrombo-inflammation and its inhibition has emerged as a potential therapeutic approach for thrombo-inflammatory disorders. Nonetheless, as of now, few small-molecule FXIIa inhibitors have demonstrated notable effectiveness against thrombo-inflammation, with none progressing into clinical stages. Herein, we present potent, covalent, reversible, and selective small-molecule FXIIa inhibitors such as 4a and 4j obtained through structure-based drug design. Compounds 4a and 4j showed significant anticoagulation and substantial anti-inflammatory effects in vitro, coupled with exceptional plasma stability. Furthermore, in carrageenan-induced thrombosis models, 4a and 4j demonstrated remarkable dual antithrombotic and anti-inflammatory activity when administered orally. Compound 4j exhibited a favorable safety profile without obvious tissue toxicity in mice, suggesting its potential as an oral therapeutic option for thrombo-inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China.
- The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
- Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
ORCID-Profile: Chenzhong Liao
Förderung
- National Natural Science Foundation of China
- Anhui Provincial Key Research and Development Plan
- Intelligent Manufacturing Institute, Hefei University of Technology
Zitieren
APA
Meng, Z., Wang, S., Chen, F., Zhang, Z., Zhang, Y., Yin, Z., Duan, Y., Zheng, N., Wang, Q., Liao, C., Chen, Y., & Xie, Z. (2024). Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00475
Vancouver
Meng Z, Wang S, Chen F, Zhang Z, Zhang Y, Yin Z, et al. Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00475
BibTeX
@article{Meng2024,
author = {Meng, Zhiwei and Wang, Shengnan and Chen, Fangrong and Zhang, Zhenzhen and Zhang, Yajing and Yin, Zequn and Duan, Yajun and Zheng, Nan and Wang, Qin and Liao, Chenzhong and Chen, Yuanli and Xie, Zhouling},
title = {Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00475}
}
EUVIMED